or Try an Advanced Search...

    Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 5.24 -3.68% -0.20
    BDTX closed down 3.68 percent on Thursday, May 16, 2024, on 2.48 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical BDTX trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    New Downtrend Bearish 0.00%
    NR7 Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other -3.68%
    Older End-of-Day Signals for BDTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 3 hours ago
    50 DMA Support about 7 hours ago
    Down 3% about 7 hours ago
    2x Volume Pace about 7 hours ago
    1.5x Volume Pace about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BDTX Chart by TradingView
    Basic chart:

    Profile

    Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment Enzymes Diamond Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Genetic Diseases Oncogenes Therapies For Cancer Protein Kinase Rare Genetic Disease Rare Genetic Diseases Black Diamond Kinase

    Is BDTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
    May 9 Black Diamond Therapeutics GAAP EPS of -$0.35 beats by $0.08
    May 9 Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 24 Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 15 Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
    Apr 11 Black Diamond Therapeutics Announces Changes to Board of Directors
    Apr 8 Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
    Apr 7 Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
    Apr 3 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    Mar 22 How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
    See more BDTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.66
    52 Week Low 1.62
    Average Volume 663,976
    200-Day Moving Average 3.63
    50-Day Moving Average 5.34
    20-Day Moving Average 5.95
    10-Day Moving Average 6.37
    Average True Range 0.51
    RSI (14) 42.20
    ADX 32.06
    +DI 25.14
    -DI 26.07
    Chandelier Exit (Long, 3 ATRs) 6.12
    Chandelier Exit (Short, 3 ATRs) 6.41
    Upper Bollinger Bands 7.46
    Lower Bollinger Band 4.44
    Percent B (%b) 0.27
    BandWidth 50.76
    MACD Line 0.15
    MACD Signal Line 0.31
    MACD Histogram -0.1688
    Fundamentals Value
    Market Cap 270.57 Million
    Num Shares 51.6 Million
    EPS -2.13
    Price-to-Earnings (P/E) Ratio -2.46
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.77
    Resistance 3 (R3) 5.81 5.68 5.68
    Resistance 2 (R2) 5.68 5.54 5.66 5.65
    Resistance 1 (R1) 5.46 5.46 5.39 5.42 5.62
    Pivot Point 5.32 5.32 5.29 5.30 5.32
    Support 1 (S1) 5.10 5.19 5.04 5.06 4.86
    Support 2 (S2) 4.97 5.10 4.95 4.83
    Support 3 (S3) 4.75 4.97 4.80
    Support 4 (S4) 4.71